Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database.

ABSTRACT:

Background

Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID-19) affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study reviews tocilizumab adverse drug events (ADEs) reported in the World Health Organization (WHO) pharmacovigilance database.

Research design and methods

All suspected ADEs associated with tocilizumab between April to August 2020 were analyzed based on COVID-19 patients' demographic and clinical variables, and severity of involvement of organ system.

Results

A total of 1005 ADEs were reported among 513 recipients. The majority of the ADEs (46.26%) were reported from 18-64 years, we

SUBMITTER: Charan J 

PROVIDER: S-EPMC8290369 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature